Access to medicinal treatment of MPS

Starting from 1 July 2012 the National Health Insurance Fund (NHIF) will reimburse the medicinal treatment of mucopolysaccharidosis (MPS). At the beginning of this year the diagnosis of MPS was included in Ordinance 38 of the Ministry of Health, as well as the relevant drug (Elaprase) in Annex 1 of the Positive Drug List. The requirements for MPS patients to undergo enzyme replacement therapy are finalised and published on the website of the NHIF.